CN1586517A - Chinese medicine preparation for treating gynecologic inflammation - Google Patents
Chinese medicine preparation for treating gynecologic inflammation Download PDFInfo
- Publication number
- CN1586517A CN1586517A CN 200410058110 CN200410058110A CN1586517A CN 1586517 A CN1586517 A CN 1586517A CN 200410058110 CN200410058110 CN 200410058110 CN 200410058110 A CN200410058110 A CN 200410058110A CN 1586517 A CN1586517 A CN 1586517A
- Authority
- CN
- China
- Prior art keywords
- solution
- adds
- preparation
- reference substance
- fine powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 67
- 238000002360 preparation method Methods 0.000 title claims abstract description 65
- 206010061218 Inflammation Diseases 0.000 title claims abstract description 38
- 230000004054 inflammatory process Effects 0.000 title claims abstract description 38
- 239000000463 material Substances 0.000 claims abstract description 17
- 235000012828 Citrullus lanatus var citroides Nutrition 0.000 claims abstract description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 69
- 239000000243 solution Substances 0.000 claims description 49
- 238000012360 testing method Methods 0.000 claims description 47
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 44
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 42
- 239000000843 powder Substances 0.000 claims description 42
- 239000000706 filtrate Substances 0.000 claims description 28
- 238000001035 drying Methods 0.000 claims description 25
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 24
- 239000000047 product Substances 0.000 claims description 23
- 239000013558 reference substance Substances 0.000 claims description 22
- 229960004756 ethanol Drugs 0.000 claims description 21
- 238000003756 stirring Methods 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 17
- 239000000829 suppository Substances 0.000 claims description 17
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims description 15
- 241000219109 Citrullus Species 0.000 claims description 14
- 239000013078 crystal Substances 0.000 claims description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 11
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 10
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 10
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 10
- 239000002244 precipitate Substances 0.000 claims description 10
- 239000000341 volatile oil Substances 0.000 claims description 10
- 206010037660 Pyrexia Diseases 0.000 claims description 9
- 239000013543 active substance Substances 0.000 claims description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 8
- 239000002994 raw material Substances 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 8
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 7
- 239000002552 dosage form Substances 0.000 claims description 7
- -1 filter Substances 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 7
- 239000006228 supernatant Substances 0.000 claims description 7
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 6
- 239000000853 adhesive Substances 0.000 claims description 6
- 230000001070 adhesive effect Effects 0.000 claims description 6
- 229930182470 glycoside Natural products 0.000 claims description 6
- 150000002338 glycosides Chemical class 0.000 claims description 6
- 239000000741 silica gel Substances 0.000 claims description 6
- 229910002027 silica gel Inorganic materials 0.000 claims description 6
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 6
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 6
- 239000011780 sodium chloride Substances 0.000 claims description 6
- 238000004809 thin layer chromatography Methods 0.000 claims description 6
- 238000004821 distillation Methods 0.000 claims description 5
- 239000003480 eluent Substances 0.000 claims description 5
- 238000010828 elution Methods 0.000 claims description 5
- 239000000945 filler Substances 0.000 claims description 5
- 239000006210 lotion Substances 0.000 claims description 5
- 238000004064 recycling Methods 0.000 claims description 5
- 239000011347 resin Substances 0.000 claims description 5
- 229920005989 resin Polymers 0.000 claims description 5
- 238000001179 sorption measurement Methods 0.000 claims description 5
- 239000007921 spray Substances 0.000 claims description 5
- 239000012085 test solution Substances 0.000 claims description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 4
- 229960000583 acetic acid Drugs 0.000 claims description 4
- 229960000935 dehydrated alcohol Drugs 0.000 claims description 4
- 238000001514 detection method Methods 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 3
- 238000007710 freezing Methods 0.000 claims description 3
- 230000008014 freezing Effects 0.000 claims description 3
- VKJGBAJNNALVAV-UHFFFAOYSA-M Berberine chloride (TN) Chemical compound [Cl-].C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 VKJGBAJNNALVAV-UHFFFAOYSA-M 0.000 claims description 2
- WTEVQBCEXWBHNA-UHFFFAOYSA-N Citral Natural products CC(C)=CCCC(C)=CC=O WTEVQBCEXWBHNA-UHFFFAOYSA-N 0.000 claims description 2
- ZSBXGIUJOOQZMP-UHFFFAOYSA-N Isomatrine Natural products C1CCC2CN3C(=O)CCCC3C3C2N1CCC3 ZSBXGIUJOOQZMP-UHFFFAOYSA-N 0.000 claims description 2
- ZSBXGIUJOOQZMP-JLNYLFASSA-N Matrine Chemical compound C1CC[C@H]2CN3C(=O)CCC[C@@H]3[C@@H]3[C@H]2N1CCC3 ZSBXGIUJOOQZMP-JLNYLFASSA-N 0.000 claims description 2
- 101100489867 Mus musculus Got2 gene Proteins 0.000 claims description 2
- 241000405070 Percophidae Species 0.000 claims description 2
- 238000003556 assay Methods 0.000 claims description 2
- 230000033228 biological regulation Effects 0.000 claims description 2
- ONBIUAZBGHXJDM-UHFFFAOYSA-J bismuth;potassium;tetraiodide Chemical compound [K+].[I-].[I-].[I-].[I-].[Bi+3] ONBIUAZBGHXJDM-UHFFFAOYSA-J 0.000 claims description 2
- 229940043350 citral Drugs 0.000 claims description 2
- 238000011067 equilibration Methods 0.000 claims description 2
- 239000003205 fragrance Substances 0.000 claims description 2
- WTEVQBCEXWBHNA-JXMROGBWSA-N geranial Chemical compound CC(C)=CCC\C(C)=C\C=O WTEVQBCEXWBHNA-JXMROGBWSA-N 0.000 claims description 2
- 239000012362 glacial acetic acid Substances 0.000 claims description 2
- 230000003760 hair shine Effects 0.000 claims description 2
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 229930014456 matrine Natural products 0.000 claims description 2
- 239000012567 medical material Substances 0.000 claims description 2
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 claims description 2
- 239000003208 petroleum Substances 0.000 claims description 2
- DHRLEVQXOMLTIM-UHFFFAOYSA-N phosphoric acid;trioxomolybdenum Chemical compound O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.OP(O)(O)=O DHRLEVQXOMLTIM-UHFFFAOYSA-N 0.000 claims description 2
- 239000000377 silicon dioxide Substances 0.000 claims description 2
- 239000002511 suppository base Substances 0.000 claims description 2
- 238000011003 system suitability test Methods 0.000 claims description 2
- 239000006216 vaginal suppository Substances 0.000 claims description 2
- 238000005303 weighing Methods 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims 1
- 238000003908 quality control method Methods 0.000 abstract description 4
- 244000241235 Citrullus lanatus Species 0.000 abstract 1
- 241000972673 Phellodendron amurense Species 0.000 abstract 1
- 235000002226 Ranunculus ficaria Nutrition 0.000 abstract 1
- 241000293861 Scrophularia nodosa Species 0.000 abstract 1
- 240000003705 Senecio vulgaris Species 0.000 abstract 1
- 241000219784 Sophora Species 0.000 abstract 1
- 230000009194 climbing Effects 0.000 abstract 1
- 229940079593 drug Drugs 0.000 description 33
- 239000008187 granular material Substances 0.000 description 20
- 210000001215 vagina Anatomy 0.000 description 19
- 241000700159 Rattus Species 0.000 description 11
- 206010008323 cervicitis Diseases 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 239000006187 pill Substances 0.000 description 10
- 239000003826 tablet Substances 0.000 description 10
- 241000283973 Oryctolagus cuniculus Species 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 206010030113 Oedema Diseases 0.000 description 7
- 239000002775 capsule Substances 0.000 description 7
- 239000000796 flavoring agent Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
- 239000008101 lactose Substances 0.000 description 6
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 5
- 208000006374 Uterine Cervicitis Diseases 0.000 description 5
- 230000005856 abnormality Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 201000003988 chronic cervicitis Diseases 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 235000019634 flavors Nutrition 0.000 description 5
- 235000008216 herbs Nutrition 0.000 description 5
- 210000004877 mucosa Anatomy 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 208000003251 Pruritus Diseases 0.000 description 4
- 206010040880 Skin irritation Diseases 0.000 description 4
- 206010046914 Vaginal infection Diseases 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 125000005456 glyceride group Chemical group 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 235000012907 honey Nutrition 0.000 description 4
- 239000000905 isomalt Substances 0.000 description 4
- 235000010439 isomalt Nutrition 0.000 description 4
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 230000037311 normal skin Effects 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 231100000915 pathological change Toxicity 0.000 description 4
- 230000036285 pathological change Effects 0.000 description 4
- 230000036556 skin irritation Effects 0.000 description 4
- 231100000475 skin irritation Toxicity 0.000 description 4
- 239000007901 soft capsule Substances 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 241000700199 Cavia porcellus Species 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 241000700157 Rattus norvegicus Species 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 230000003118 histopathologic effect Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000007794 irritation Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000222122 Candida albicans Species 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 206010018691 Granuloma Diseases 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 201000008100 Vaginitis Diseases 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- 208000038016 acute inflammation Diseases 0.000 description 2
- 230000006022 acute inflammation Effects 0.000 description 2
- 210000004100 adrenal gland Anatomy 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 229940095731 candida albicans Drugs 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 210000003679 cervix uteri Anatomy 0.000 description 2
- 230000013872 defecation Effects 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 230000001850 reproductive effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000035943 smell Effects 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 210000003932 urinary bladder Anatomy 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- LXAHHHIGZXPRKQ-UHFFFAOYSA-N 5-fluoro-2-methylpyridine Chemical compound CC1=CC=C(F)C=N1 LXAHHHIGZXPRKQ-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 208000004926 Bacterial Vaginosis Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- VYZAHLCBVHPDDF-UHFFFAOYSA-N Dinitrochlorobenzene Chemical group [O-][N+](=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 VYZAHLCBVHPDDF-UHFFFAOYSA-N 0.000 description 1
- 206010013789 Dry throat Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 208000034693 Laceration Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Natural products OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 206010061926 Purulence Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241001502500 Trichomonadida Species 0.000 description 1
- 241000202921 Ureaplasma urealyticum Species 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 201000007096 Vulvovaginal Candidiasis Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 206010048245 Yellow skin Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 201000010442 acute cervicitis Diseases 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000002052 anaphylactic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000002565 arteriole Anatomy 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 description 1
- 229910000020 calcium bicarbonate Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 208000011404 female reproductive system disease Diseases 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 201000005630 leukorrhea Diseases 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 238000005325 percolation Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 150000003376 silicon Chemical class 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 229940080313 sodium starch Drugs 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- ZAVXXBAIPSQJGS-UHFFFAOYSA-B tetracalcium;tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O.[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O.[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O ZAVXXBAIPSQJGS-UHFFFAOYSA-B 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000003371 toe Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 206010046901 vaginal discharge Diseases 0.000 description 1
- 229940120293 vaginal suppository Drugs 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to one kind of Chinese medicine preparation for treating gynecologic inflammation and its preparation process and quality control method. The Chinese medicine preparation is prepared with Chinese medicinal materials including flavescent figwort, climbing groundsel, sophora root, phellodendron bark, watermelon frost, etc.
Description
Technical field:
The present invention relates to a kind of Chinese medicine preparation for the treatment of gynecological inflammation and preparation method thereof, method of quality control, particularly relate to the pharmaceutical preparation made from Chinese medicines such as Radix Picriae felterrae, Herba Senecionis Scandentis, Radix Sophorae Flavescentis, Cortex Phellodendri, watermelon crystal, Fructus Litseae, Borneolum Syntheticums.
Background technology:
Gynecological inflammation is women's a commonly encountered diseases, gynaecological inflammation disease mainly comprises vaginitis, cervicitis, pelvic inflammatory disease etc., wherein chronic cervicitis is the most common a kind of inflammation disease of female reproductive system, its incidence rate accounts for the 40%-60% of gynecological's outpatient service sum, how not thorough because of the acute cervicitis treatment, pathogen is hidden in and forms chronic inflammatory disease in the neck tube mucosa, also can cause, see in that the women married, that body is empty is more more because of childbirth, dilatation and curettage, miscarriage or other uteroventral operations cause the laceration of cervix secondary infection." Chinese mother and child care " survey result: all kinds of gynecological inflammations such as female private part pruritus, leucorrhoea grow in quantity, lower body abnormal flavour and disease etc. in the adult female sickness rate up to more than 69%, wherein chronic cervicitis and cervical erosion are respectively 39.1% and 26.1%, are bacterial vaginitis 5.3%, monilial vaginitis 4.8%, chronic pelvic inflammatory disease 4.1% secondly.Chronic cervicitis is the hidden focus that causes pelvic cavity viscera or other organ inflammation of health, and with the substantial connection that has of cervical cancer.Therefore, chronic cervicitis and colpitic medicine are treated and prevented in searching, exploitation safely and effectively is one of great problem.
Cervicitis belongs to the category of " leukorrheal diseases " in the Gynecology of Chinese Medicine.Chinese medicine thinks that leukorrheal diseases are commonly encountered diseases, frequently-occurring diseases of women, increases with the leukorrhagia amount, and color, matter, abnormal smells from the patient are its main symptom unusually, and this is similar to cervicitis, colpitic main clinic symptoms.Its pathogeny be because of damp for suffering from, influence is appointed, is with two arteries and veins, so that dai channel fails to keep an appointment, and conception vessel solid be disease.The generation of damp or because of insufficiency of the spleen mistake fortune, water-damp not being transformed; Or solid because of the mistake of suffering from a deficiency of the kidney, envelope is hidden mistake department; Or careless because of health preserving, experience external damp, and we's selected topic institute is the patient of damp invasion of lower energizer at the person.
The medicine of existing treatment gynecological inflammation belongs to a bit cures the symptoms, not the disease, and some uses expensive material, and some interrupts use because uncertain therapeutic efficacy is cut in application process.
The invention provides a kind of determined curative effect, safe ready, the little pure traditional Chinese compound medicine of side effect.
The present invention adopts the local herb resource in Guangxi, according to Chinese medical theory, in conjunction with modern pharmacological research and checking, provides a kind of cervix uteri inflammation definite effect, compound Chinese medicinal preparation easy to use for the treatment of.
Summary of the invention:
The invention provides a kind of traditional Chinese compound medicine preparation, said preparation is made by following Chinese medicinal raw materials.
Radix Picriae felterrae 20～500g, Herba Senecionis Scandentis 20～450g, Radix Sophorae Flavescentis 20～400g, Cortex Phellodendri 20～400g, watermelon crystal 4～50g, Fructus Litseae 20～500g, Borneolum Syntheticum 1～10g.
Preferably:
Radix Picriae felterrae 180g, Herba Senecionis Scandentis 150g, Radix Sophorae Flavescentis 130g, Cortex Phellodendri 130g, watermelon crystal 4g, Fructus Litseae 170g, Borneolum Syntheticum 4g.。
In more than forming, weight is calculated with crude drug, and this composition can be made into 100 doses of the pharmaceutical preparatioies of unit dose, described 100 doses of fingers, the final drug preparation of making, as make 1000 of capsule preparations, 100 in tablet, 100 of suppositorys, 100 bags of granules, oral liquid 100 ampoules etc., also can make big packing as granule, as the 10-50 bag, specifically can be 10 bags, 12 bags, 20 bags, 25 bags, 50 bags etc., every bag can be used as taking dose 1 time.
More than form, can be made into the preparation of 5-100 taking dose,, make 100 as suppository
Tablet is made 100, and each taking dose can be 1-20 grain or sheet, can take 5-100 time altogether.As granule, make 20 bags, take the 1-2 bag at every turn, can take 10-20 time altogether.
More than form to be by weight as proportioning, when producing, can increase or reduce according to corresponding proportion, as large-scale production can be unit with the kilogram, or be unit with the ton, small-scale production can be unit with the milligram also, weight can increase or reduce, but the constant rate of the raw medicinal herbs weight proportion between each composition.
The ratio of above weight proportion obtains through science screening, and is fat or modest as serious symptom or light disease for especial patient, and the proportioning of the amount of can corresponding adjustment forming increases or reduce being no more than 100%, and drug effect is constant.
Raw material of Chinese medicine, especially ministerial drug and adjuvant drug in more than forming also can be replaced by the suitable Chinese medicine with identical property of medicine, and its drug effect of the Chinese medicine preparation after the replacement is constant.Chinese medicine preparation of the present invention is to process through extraction or other modes by the raw material of Chinese medicine that above-mentioned prescription is formed, and makes pharmaceutically active substance, subsequently, with this material is raw material, adds the medicine acceptable carrier when needing, and makes according to the routine techniques of galenic pharmacy.Described active substance can obtain by extracting raw material of Chinese medicine respectively, also can obtain by the co-extracted raw material of Chinese medicine, also can obtain by other modes, as: by pulverize, squeeze, calcine, grind, sieve, percolation, extraction, water are carried, alcohol extraction, ester are carried, methods such as ketone is carried, chromatography obtain, these active substances can be the material of extractum form, can be that dry extract also can be a fluid extract, make different concentration according to the different needs decision of preparation.
Pharmaceutically active substance in the pharmaceutical preparation of the present invention, its shared percentage by weight in preparation can be 0.1-99.9%, all the other are the medicine acceptable carrier.Pharmaceutical preparation of the present invention exists with unit dosage form, and described unit dosage form is meant the unit of preparation, as every of tablet, capsular every capsules, every of injection etc., in the unit dose, the amount that contains active substance is 5-800mg, preferably 50-500mg.
Pharmaceutical preparation of the present invention can be any pharmaceutically useful dosage form, these dosage forms comprise: tablet, capsule, oral liquid, syrup, granule, pill, powder, unguentum, sublimed preparation, injection, suppository, spray, drop pill, patch, slow releasing preparation, controlled release preparation, preferably suppository, particularly vaginal suppository.
Pharmaceutical preparation of the present invention, the preparation of its oral administration can contain excipient commonly used, such as binding agent, filler, diluent, tablet agent, lubricant, disintegrating agent, coloring agent, flavoring agent and wetting agent, can carry out coating to tablet in case of necessity.
The filler that is suitable for comprises cellulose, mannitol, lactose and other similar filler.Suitable disintegrating agent comprises starch, polyvinylpyrrolidone and starch derivatives, for example sodium starch glycollate.Suitable lubricant comprises, for example magnesium stearate.The acceptable wetting agent of appropriate drug comprises sodium lauryl sulphate.
Can fill by mixing, the method that tabletting etc. are commonly used prepares solid oral composition.Mix repeatedly active substance is distributed in those compositionss of a large amount of filleies of whole use.The form of oral liquid for example can be aqueous or oily suspensions, solution, Emulsion, syrup or elixir, perhaps can be a kind of available water before use or other suitable composite dry products of carrier.This liquid preparation can contain conventional additive, such as suspending agent, for example sorbitol, syrup, methylcellulose, gelatin, hydroxyethyl-cellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenation edible fat, emulsifying agent, for example lecithin, anhydro sorbitol monooleate or arabic gum; Non-aqueous carrier (they can comprise edible oil), for example almond oil, fractionated coconut oil, such as oily ester, propylene glycol or the ethanol of the ester of glycerol; Antiseptic, for example para hydroxybenzene methyl ester or propyl p-hydroxybenzoate or sorbic acid, and if desired, can contain conventional flavouring agent or see toner.
For injection, the liquid unit dosage forms of preparation contains active substance of the present invention and sterile carrier.According to carrier and concentration, this chemical compound can be suspended or dissolving.The preparation of solution is normally by being dissolved in active substance in a kind of carrier filter-sterilized before it is packed into a kind of suitable bottle or ampoule, sealing then.For example a kind of local anesthetic of adjuvant, antiseptic and buffer agent also can be dissolved in this carrier.In order to improve its stability, can be after the bottle of packing into that this compositions is freezing, and under vacuum, water is removed.
Pharmaceutical preparation of the present invention, when being prepared into medicament, optionally add suitable medicine acceptable carrier, described medicine acceptable carrier is selected from: mannitol, sorbitol, sodium pyrosulfite, sodium sulfite, sodium thiosulfate, cysteine hydrochloride, TGA, methionine, vitamin C, the EDTA disodium, EDTA calcium sodium, the alkali-metal carbonate of monovalence, acetate, phosphate or its aqueous solution, hydrochloric acid, acetic acid, sulphuric acid, phosphoric acid, aminoacid, sodium chloride, potassium chloride, sodium lactate, xylitol, maltose, glucose, fructose, dextran, glycine, starch, sucrose, lactose, mannitol, silicon derivative, cellulose and derivant thereof, alginate, gelatin, polyvinylpyrrolidone, glycerol, soil temperature 80, agar, calcium carbonate, calcium bicarbonate, surfactant, Polyethylene Glycol, cyclodextrin, beta-schardinger dextrin-, the phospholipid material, Kaolin, Pulvis Talci, calcium stearate, magnesium stearate etc.Pharmaceutical preparation of the present invention, its function cure mainly and are heat clearing and damp drying, killing parasites for relieving itching, convergence granulation promoting.Be used for chronic cervicitis, vaginitis, syndrome of dampness-heat diffusing downward.Disease is seen profuse leukorrhea, yellow skin or white, or be yellowish purulence, foul smell is arranged, or companion's pudendal pruritus, bitter taste in the mouth and dry throat, red tongue, yellow and greasy fur, slippery and rapid pulse.
The usage and dosage of pharmaceutical preparation of the present invention, particularly suppository is: vagina administration.Begin medication in menstruation after clean 2～3 days, one time 1,1 time on the one, 10 days is a course of treatment.
Preparation of the present invention is determined usage and dosage according to patient's situation in use, but obeys 1-4 time every day, each 1-20 agent, as: 1-20 grain or sheet.
Preparation of the present invention, different preparations can adopt following method preparation:
Prescription: Radix Picriae felterrae 20～500g, Herba Senecionis Scandentis 20～450g, Radix Sophorae Flavescentis 20～400g, Cortex Phellodendri 20～400g, watermelon crystal 4～50g, Fructus Litseae 20～500g, Borneolum Syntheticum 1～10g.
More than seven flavors, Radix Picriae felterrae adds 3～12 times of water gagings and decocts 1～3 time, each 0.5～3 hour, collecting decoction, centrifugal, styrene tyle macroporous adsorption resin on the filtrate, the water eluting discards water lotion, use 20～95% ethanol and water elution more successively, merge eluent, reclaim ethanol, being concentrated into relative density is 1.05～1.35 (60 ℃), drying is ground into fine powder, and is standby; Herba Senecionis Scandentis, Radix Sophorae Flavescentis add 3～12 times of water gagings and decoct secondary, each 0.5～3 hour, collecting decoction, filter, it is 1.02～1.40 (60 ℃) that filtrate is concentrated into relative density, adds 85% ethanol and makes and contain the alcohol amount and reach 60%, fully stir, left standstill 4～24 hours, get supernatant, filter, filtrate recycling ethanol, being concentrated into relative density is 1.02～1.40 (60 ℃), drying, be ground into fine powder, standby; Cortex Phellodendri adds 3～12 times of amount 0.1～2.0% sulfuric acid solutions, decocts secondary, each 0.5～3 hour, collecting decoction filtered, filtrate is concentrated into 1.01～1.20 (60 ℃), adds the sodium chloride that is equivalent to extractum amount 15%, stirs, leave standstill, centrifugal, precipitate washes with water to pH value 2～7, and is centrifugal, drying precipitate, be ground into fine powder, standby; The watermelon crystal drying, be ground into fine powder, with above-mentioned fine powder mixing; Fructus Litseae adds 3～12 times of water gaging distillations 3～12 hours, collects volatile oil, and is standby; Borneolum Syntheticum powder is broken into fine powder, adds in the above-mentioned volatile oil, and slight fever makes dissolving, adds in the above-mentioned fine powder again, stirs evenly;
The preparation of suppository: get mixed fatty glycerides, heating makes fusing, adds said mixture, stirs, and pours into into 100, and cooling is sealed, and shears, promptly.
The preparation of tablet, capsule: granulate, add appropriate amount of auxiliary materials, make granule, tabletting or incapsulate is made 100 or 100.
The preparation of granule: add appropriate amount of auxiliary materials (Icing Sugar, lactose or isomalt etc.), make granule, drying is made 100 bags.
Preparation of soft capsule: add an amount of Polyethylene Glycol, mixing is pressed into 100.The preparation of pill: add an amount of refined honey, water, make honeyed pill.
Below by pharmacodynamic study data declaration beneficial effect of the present invention:
Used medicine is the suppository of the embodiment of the invention 3 methods preparation in the experiment, stops bolt in this called after woman inflammation.
1, external resisting pathogenic microbes result of the test shows: select 5 kinds of pathogenic bacterium with the primary disease height correlation, every kind of pathogenic bacteria is adopted 5 different clinical strains, wherein staphylococcus aureus and escherichia coli have also respectively been adopted 1 strain reference culture, observe woman's inflammation and stop the outer bacteriostasis of key.Result of the test shows that woman's inflammation stops bolt Candida albicans is had stronger inhibitory action, the MIC scope is 0.0809～0.0404g crude drug/ml, escherichia coli, staphylococcus aureus, Hemolytic streptococcus, gonococcus are also had the obvious suppression effect, and MIC is respectively 0.1619～0.0404g crude drug/ml, 0.1619～0.0809g crude drug/ml, 0.1619～0.0809g crude drug/ml, 0.1619～0.0809g crude drug/ml.In addition, this product is external also to have inhibitory action to ureaplasma urealyticum, and MIC is 0.1619g crude drug/ml; Woman's inflammation stops that bolt extracorporeal corrosioning vagina wool trichomonad result of the test shows that this product is 0.3238,0.1619,0.0809,0.0404 in concentration, during 0.0202g crude drug/ml, after 4,4,8,8,16 hours infusorian is had killing action in effect respectively.
2, rabbit colpitis mycotica result of the test shows: woman's inflammation is stopped bolt 0.76g crude drug/kg, 0.38g crude drug/kg can obviously promote animal pattern Candida albicans turn out cloudy (P＜0.01), can obviously improve the local symptom (P＜0.05, P＜0.01) of rabbit colpitis mycotica.
3, the tentative cervicitis result of the test of rabbit shows: woman's inflammation is stopped bolt 0.76g crude drug/kg, 0.38g crude drug/kg can obviously reduce modeling animal cervical tissue PGE
2Content (P＜0.05, P＜0.01), significantly improve simultaneously the histologic lesion (P＜0.05, P＜0.01) of the tentative cervicitis of rabbit.
4, the antiinflammatory result of the test shows: woman's inflammation is stopped bolt 2.54g crude drug/kg, 1.27g crude drug/kg, 0.64 crude drug/kg all has obvious suppression effect (P＜0.05, P＜0.01) to mouse knoting oil auricle edema, rat agar granuloma and granuloma induced by implantation of cotton pellets; The swelling of rat toes also has obvious suppression effect (P＜0.05, P＜0.01) due to the on Carrageenan.
5, the putrefaction-removing granulation-promoting result of the test shows: woman's inflammation is stopped the ulcer surface healing rate (P＜0.05, P＜0.01) that bolt 1.52g crude drug/kg, 0.76g crude drug/kg can obviously improve rat model.
6, Mice Auricle microcirculation result of the test shows: woman's inflammation is stopped bolt 2.54g crude drug/kg, 1.27g crude drug/kg can make Mice Auricle arteriole (A), thin vein (V) external caliber obviously increase, the open quantity of auricle blood capillary increases (P＜0.05, P＜0.01).
7, the analgesic test result shows: woman's inflammation is stopped the number of times (P＜0.05) that bolt 2.54g crude drug/kg, 1.27g crude drug/kg can obviously reduce acetic acid induced mice writhing response; Woman's inflammation is stopped each dosage group of bolt and the comparison of blank group there are no significant difference (P＞0.05) in the hot plate method test, but certain inhibitory action trend is arranged.
8, antipruritic result of the test shows: woman's inflammation is stopped bolt 1.52g crude drug/kg has obvious suppression effect (P＜0.05) to guinea pig skin pruritus due to the histamine.
(2), toxicological study
1, acute toxicity test
Get the Wistar rat and be divided into normal vagina and damaged vagina test group, each rats in test groups is stopped the bolt accumulation respectively at contact woman inflammation in 24 hours and is reached 16.87g crude drug/kg, be equivalent to clinical day consumption (133 times of 7.61g crude drug/60kg) of intending of people, 7 days per vaginam mouths there is no tangible hyperemia, edema reaction after reaching drug withdrawal during the administration, rat general activity, appetite, spirit, defecation and body weight gain no abnormality seen are not seen animal dead yet.
2, long term toxicity test
Get the Wistar rat and be divided into normal vagina and damaged vagina test group.Each rats in test groups gives respectively that dosage is 8.435,4.218, woman's inflammation of 2.109g raw medicinal herbs/kg is stopped bolt (be equivalent to the people approximately respectively and intended 66.4,33.2,16.6 times of consumption in clinical day), in continuous 12 weeks, continues after the drug withdrawal to observe for 3 weeks.The result shows, each observation index and matched group comparisons such as general situation, hematology and the blood parameters of three dosage treated animals of normal vagina and damaged vagina test group, organ coefficient, no abnormality seen.Histopathology is observed each high dose (8.435g raw medicinal herbs/kg, being equivalent to clinical day 66.4 times of intending consumption of people) liver and the nephropathy example number of group have increase, but organs such as the heart of middle dosage (4.218g raw medicinal herbs/kg is equivalent to clinical day 33.2 times of intending consumption of people) group, liver,kidney,spleen, lung, brain, thymus, adrenal gland, stomach, small intestinal, bladder, vagina, uterus, ovary there is no pathological change.Drug withdrawal 3 week, the back continued to observe, and woman's inflammation is stopped organ such as the heart, liver,kidney,spleen, lung, brain, thymus, adrenal gland, stomach, small intestinal, bladder, vagina, uterus, ovary of bolt height, middle dosage group and be there is no pathological change.The result shows that woman's inflammation stops that the safe dose of bolt is 4.218,2.109g raw medicinal herbs/kg.
3, the test that the female rats reproductive performance is influenced
Get the Wistar rat and give respectively that dosage is 8.435,4.218, woman's inflammation of 2.109g crude drug/kg is stopped bolt (be equivalent to the people approximately respectively and intended 66.4,33.2,16.6 times of consumption in clinical day), after 12 weeks, the back mated for 4 weeks with male rat through the rat vagina successive administration.The result shows that the pregnancy rate of the jenny of three dosage groups, motherhood time, litter size and blank group are not seen significant difference, and the tire weight of living also no abnormality seen changes, and young Mus outward appearance is ruddy, and naked eyes there is no deformity, and each administration group does not see that stillborn fetus is arranged.The result shows that woman's inflammation stops bolt the female rats reproductive performance is not seen toxic reaction.
4, vaginal mucosa irritation, skin irritation and skin anaphylactic test
The vaginal mucosa irritation result of the test shows: rat vagina gives woman's inflammation and stops suppository and be subjected to test solution 0.5ml/kg (1.62g crude drug/kg), observe the vaginal mucosa irritation of normal vagina and damaged vagina single and multiple dosing.The result shows, respectively organizes the no abnormal secretions of rat vagina mouth, the general situation of whole body (appetite, spirit, defecation etc.) no abnormality seen after single and the multiple dosing drug withdrawal in 24 hours.Vaginal mucosa perusal no abnormality seen secretions after the drug withdrawal after 24 hours, hemorrhage, edema, ulcer and rotten to the corn downright bad.The result of histopathologic examination shows, normal vagina woman inflammation stops that vagina tissue structure and cellular morphology there is no abnormal change behind bolt group, substrate matched group and blank group single and the multiple dosing, vagina tissue had acute inflammation to change after woman's inflammation of damaged vagina test group was stopped bolt group, substrate matched group and blank group single and multiple dosing, but routine number there was no significant difference between each group.
Rabbit skin irritation test is the result show: woman's inflammation is stopped bolt normal skin and damaged skin single-dose, rabbit skin is skin irritation reactions such as show speckle, edema not, intensity evaluation belongs to nonirritant, the result of histopathologic examination shows, each is organized the rabbit normal skin and there is no pathological change, and injured skin all has the part acute inflammation to change; Woman's inflammation is stopped bolt normal skin and damaged skin multiple dosing, rabbit skin is skin irritation reactions such as show speckle, edema not, intensity evaluation belongs to nonirritant, the result of histopathologic examination shows, each is organized the rabbit normal skin and there is no pathological change, injured skin all has inflammation to change, but downright bad routine number there was no significant difference between each group.
The guinea pig skin hypersensitive test is the result show: erythema, edema obviously appear in positive control drug 2,4-dinitrochlorobenzene group guinea pig skin, the sensitization rate is 100%, blank group, substrate matched group, woman's inflammation is stopped the bolt group does not all have erythema, edema, does not see the skin hypersensitivity reaction.
The present invention also provides the method for quality control of pharmaceutical preparation of the present invention, particularly suppository:
Method of quality control of the present invention comprises following content:
For suppository,
Character: this product is that yellowish-brown is to brown duckbill suppository; Special fragrance is arranged.
Differentiate: (1) gets 1 of this product, puts in the tool plug conical flask, and slight fever makes fusing, the 20ml that adds diethyl ether, and close plug jolting 2 minutes filters, and medicinal residues are standby, and filtrate is as need testing solution.Other gets the Borneolum Syntheticum reference substance, adds dehydrated alcohol and makes the solution that every 1ml contains 2mg; Get the citral reference substance again, add dehydrated alcohol and make the solution that every 1ml contains 5 μ l, in contrast product solution.Test according to thin layer chromatography (appendix VIB of Chinese Pharmacopoeia version in 2000), draw each 1 μ l of above-mentioned three kinds of solution, put respectively in same be on the silica gel g thin-layer plate of adhesive with the sodium carboxymethyl cellulose, with petroleum ether (30 ~ 60 ℃)-ethyl acetate-benzene (12: 1: 2) is developing solvent, launch, take out, dry, spray is with the phosphomolybdic acid test solution, and it is clear to be heated to the speckle colour developing at 105 ℃.In the test sample chromatograph, with the corresponding position of reference substance chromatograph on, show the speckle of same color.
(2) get the medicinal residues under the item of [discriminating] (1), volatilize ether, add methanol 10ml, supersound process 20 minutes filters, and filtrate is as need testing solution.Other gets Cortex Phellodendri control medicinal material 0.15g, adds methanol 5ml, shines medical material solution in pairs with legal system.Get the berberine hydrochloride reference substance again, add methanol and make the solution that every 1ml contains 0.5mg, in contrast product solution.Test according to thin layer chromatography (appendix VIB of Chinese Pharmacopoeia version in 2000), draw each 2 ~ 4 μ l of above-mentioned three kinds of solution, put respectively in same be on the silica gel g thin-layer plate of adhesive with the sodium carboxymethyl cellulose, with benzene-ethyl acetate-methanol-isopropyl alcohol-strong ammonia solution (12: 6: 3: 3: 1) is developing solvent, with developing solvent and strong ammonia solution pre-equilibration 15 minutes simultaneously, launch, take out, dry, put under the ultra-violet lamp (365nm) and inspect.In the test sample chromatograph, with control medicinal material chromatograph and the corresponding position of reference substance chromatograph on, show the fluorescence speckle of same color.
(3) get 1 of this product, put in the tool plug conical flask, slight fever makes fusing, the 20ml that adds diethyl ether, close plug jolting 2 minutes, filter, medicinal residues volatilize ether, add chloroform 30ml, strong ammonia solution 0.5ml, supersound process 30 minutes, filter, filtrate evaporate to dryness, residue add chloroform 2ml makes dissolving, as need testing solution.Other gets the matrine reference substance, adds methanol and makes the solution that every 1ml contains 0.5mg, in contrast product solution.Test according to thin layer chromatography (appendix VIB of Chinese Pharmacopoeia version in 2000), draw need testing solution 4～6 μ l, reference substance solution 4 μ l, put respectively in same be on the silica gel g thin-layer plate of adhesive with the sodium carboxymethyl cellulose, with benzene-acetone-ethyl acetate-strong ammonia solution (2: 3: 4: 0.2) be developing solvent, launch, take out, dry, spray is with bismuth potassium iodide test solution.In the test sample chromatograph, with the corresponding position of reference substance chromatograph on, show the speckle of same color.
Check: pH value is got 2 of this product, adds water 40ml, puts in the hot bath, makes fusing, stirs, and puts coldly, filters, and measures (appendix VIIG of Chinese Pharmacopoeia version in 2000) in accordance with the law, should be 4.0～5.5.
Other should meet every regulation relevant under the suppository item (appendix IW of Chinese Pharmacopoeia version in 2000).
Assay: measure according to high performance liquid chromatography (appendix VID of Chinese Pharmacopoeia version in 2000).
Chromatographic condition and system suitability test are filler with octadecylsilane chemically bonded silica; Acetonitrile-water-glacial acetic acid (38: 62: 0.5) is a mobile phase; The detection wavelength is 264nm.Number of theoretical plate is pressed Radix Picriae felterrae glycosides I
AThe peak calculates should be not less than 5000.
The preparation of reference substance solution: precision takes by weighing Radix Picriae felterrae glycosides I
AReference substance is an amount of, adds methanol and makes the solution that every 1ml contains 0.1mg, in contrast product solution.
10 of this product are got in the preparation of need testing solution, and accurate the title decides, and grinds, and gets about 2g, the accurate title, decide, and puts in the tool plug conical flask, and the accurate methanol 20ml that adds claims to decide weight, supersound process 45 minutes is put coldly, claims to decide weight again, supplies the weight that subtracts mistake with methanol, shake up, filter, getting subsequent filtrate, to put refrigerator freezing, after treating that suppository base solidifies, take out, centrifugal, get supernatant, be placed to room temperature, promptly.
Accurate respectively reference substance solution and each the 20 μ l of need testing solution of drawing of algoscopy inject chromatograph of liquid, measure, and calculate, promptly.
Every of this product contains Radix Picriae felterrae with Radix Picriae felterrae glycosides I
A(C
41H
62O
13) meter, must not be less than 1.6mg.
The specific embodiment:
Embodiment 1
Prescription: Radix Picriae felterrae 500g, Herba Senecionis Scandentis 450g, Radix Sophorae Flavescentis 400g, Cortex Phellodendri 400g, watermelon crystal 50g, Fructus Litseae 500g, Borneolum Syntheticum 10g.
More than seven flavors, Radix Picriae felterrae adds 3 times of water gagings and decocts 1 time, each 0.5 hour, collecting decoction, centrifugal, styrene tyle macroporous adsorption resin on the filtrate, the water eluting discards water lotion, use 20% ethanol and water elution more successively, merge eluent, reclaim ethanol, being concentrated into relative density is 1.05 (60 ℃), drying is ground into fine powder, and is standby; Herba Senecionis Scandentis, Radix Sophorae Flavescentis add 3 times of water gagings and decoct secondary, each 0.5 hour, collecting decoction, filter, it is 1.02 (60 ℃) that filtrate is concentrated into relative density, adds 85% ethanol and makes and contain the alcohol amount and reach 60%, fully stir, left standstill 4 hours, get supernatant, filter, filtrate recycling ethanol, being concentrated into relative density is 1.02 (60 ℃), drying, be ground into fine powder, standby; Cortex Phellodendri adds 3 times of amount 0.1% sulfuric acid solutions, decocts secondary, each 0.5 hour, collecting decoction filtered, filtrate is concentrated into 1.01 (60 ℃), adds the sodium chloride that is equivalent to extractum amount 15%, stirs, leave standstill, centrifugal, precipitate washes with water to pH value 2, and is centrifugal, drying precipitate, be ground into fine powder, standby; The watermelon crystal drying, be ground into fine powder, with above-mentioned fine powder mixing; Fructus Litseae adds 3 times of water gaging distillations 3 hours, collects volatile oil, and is standby; Borneolum Syntheticum powder is broken into fine powder, adds in the above-mentioned volatile oil, and slight fever makes dissolving, adds in the above-mentioned fine powder again, stirs evenly;
The preparation of suppository: get mixed fatty glycerides, heating makes fusing, adds said mixture, stirs, and pours into into 100, and cooling is sealed, and shears, promptly.
The preparation of tablet, capsule: granulate, add appropriate amount of auxiliary materials, make granule, tabletting or incapsulate is made 100 or 100.
The preparation of granule: add appropriate amount of auxiliary materials (Icing Sugar, lactose or isomalt etc.), make granule, drying is made 100 bags.
Preparation of soft capsule: add an amount of Polyethylene Glycol, mixing is pressed into 100.
The preparation of pill: add an amount of refined honey, water, make honeyed pill.
Embodiment 2
Prescription: Radix Picriae felterrae 500g, Herba Senecionis Scandentis 450g, Radix Sophorae Flavescentis 400g, Cortex Phellodendri 400g, watermelon crystal 50g, Fructus Litseae 500g, Borneolum Syntheticum 10g.
More than seven flavors, Radix Picriae felterrae adds 12 times of water gagings and decocts 3 times, each 3 hours, collecting decoction, centrifugal, styrene tyle macroporous adsorption resin on the filtrate, the water eluting discards water lotion, use 95% ethanol and water elution more successively, merge eluent, reclaim ethanol, being concentrated into relative density is 1.35 (60 ℃), drying is ground into fine powder, and is standby; Herba Senecionis Scandentis, Radix Sophorae Flavescentis add 12 times of water gagings and decoct secondary, each 3 hours, collecting decoction, filter, it is 1.40 (60 ℃) that filtrate is concentrated into relative density, adds 85% ethanol and makes and contain the alcohol amount and reach 60%, fully stir, left standstill 24 hours, get supernatant, filter, filtrate recycling ethanol, being concentrated into relative density is 1.40 (60 ℃), drying, be ground into fine powder, standby; Cortex Phellodendri adds 12 times of amount 2.0% sulfuric acid solutions, decocts secondary, each 3 hours, collecting decoction filtered, filtrate is concentrated into 1.20 (60 ℃), adds the sodium chloride that is equivalent to extractum amount 15%, stirs, leave standstill, centrifugal, precipitate washes with water to pH value 7, and is centrifugal, drying precipitate, be ground into fine powder, standby; The watermelon crystal drying, be ground into fine powder, with above-mentioned fine powder mixing; Fructus Litseae adds 12 times of water gaging distillations 12 hours, collects volatile oil, and is standby; Borneolum Syntheticum powder is broken into fine powder, adds in the above-mentioned volatile oil, and slight fever makes dissolving, adds in the above-mentioned fine powder again, stirs evenly;
The preparation of suppository: get mixed fatty glycerides, heating makes fusing, adds said mixture, stirs, and pours into into 100, and cooling is sealed, and shears, promptly.
The preparation of tablet, capsule: granulate, add appropriate amount of auxiliary materials, make granule, tabletting or incapsulate is made 100 or 100.
The preparation of granule: add appropriate amount of auxiliary materials (Icing Sugar, lactose or isomalt etc.), make granule, drying is made 100 bags.
Preparation of soft capsule: add an amount of Polyethylene Glycol, mixing is pressed into 100.
The preparation of pill: add an amount of refined honey, water, make honeyed pill.
Embodiment 3
Prescription: Radix Picriae felterrae 250g, Herba Senecionis Scandentis 225g, Radix Sophorae Flavescentis 200g, Cortex Phellodendri 200g, watermelon crystal 25g, Fructus Litseae 250g, Borneolum Syntheticum 5g.
More than seven flavors, Radix Picriae felterrae adds 8 times of water gagings and decocts 2 times, each 2 hours, collecting decoction, centrifugal, styrene tyle macroporous adsorption resin on the filtrate, the water eluting discards water lotion, use 70% ethanol and water elution more successively, merge eluent, reclaim ethanol, being concentrated into relative density is 1.25 (60 ℃), drying is ground into fine powder, and is standby; Herba Senecionis Scandentis, Radix Sophorae Flavescentis add 8 times of water gagings and decoct secondary, each 2 hours, collecting decoction, filter, it is 1.25 (60 ℃) that filtrate is concentrated into relative density, adds 85% ethanol and makes and contain the alcohol amount and reach 60%, fully stir, left standstill 12 hours, get supernatant, filter, filtrate recycling ethanol, being concentrated into relative density is 1.25 (60 ℃), drying, be ground into fine powder, standby; Cortex Phellodendri adds 8 times of amount 1% sulfuric acid solutions, decocts secondary, each 2 hours, collecting decoction filtered, filtrate is concentrated into 1.05 (60 ℃), adds the sodium chloride that is equivalent to extractum amount 15%, stirs, leave standstill, centrifugal, precipitate washes with water to pH value 5, and is centrifugal, drying precipitate, be ground into fine powder, standby; The watermelon crystal drying, be ground into fine powder, with above-mentioned fine powder mixing; Fructus Litseae adds 8 times of water gaging distillations 8 hours, collects volatile oil, and is standby; Borneolum Syntheticum powder is broken into fine powder, adds in the above-mentioned volatile oil, and slight fever makes dissolving, adds in the above-mentioned fine powder again, stirs evenly;
The preparation of suppository: get mixed fatty glycerides, heating makes fusing, adds said mixture, stirs, and pours into into 100, and cooling is sealed, and shears, promptly.
The preparation of tablet, capsule: granulate, add appropriate amount of auxiliary materials, make granule, tabletting or incapsulate is made 100 or 100.
The preparation of granule: add appropriate amount of auxiliary materials (Icing Sugar, lactose or isomalt etc.), make granule, drying is made 100 bags.
Preparation of soft capsule: add an amount of Polyethylene Glycol, mixing is pressed into 100.
The preparation of pill: add an amount of refined honey, water, make honeyed pill.
Claims (10)
1. Chinese medicine preparation for the treatment of gynecological inflammation, it is characterized in that, per 100 dosage units are made by following Chinese medicinal raw materials, Radix Picriae felterrae 20～500g, Herba Senecionis Scandentis 20～450g, Radix Sophorae Flavescentis 20～400g, Cortex Phellodendri 20～400g, watermelon crystal 4～50g, Fructus Litseae 20～500g, Borneolum Syntheticum 1～10g.
2. the Chinese medicine preparation of claim 1 is characterized in that, per 100 dosage units are made by following Chinese medicinal raw materials, Radix Picriae felterrae 180g, Herba Senecionis Scandentis 150g, Radix Sophorae Flavescentis 130g, Cortex Phellodendri 130g, watermelon crystal 4g, Fructus Litseae 170g, Borneolum Syntheticum 4g.
3. the Chinese medicine preparation of claim 1-2 is to be fit to medicinal various dosage forms.
4. the Chinese medicine preparation of claim 3 is a suppository.
5. the Chinese medicine preparation of claim 4 is vaginal suppositories.
6. the Chinese medicine preparation of claim 1 wherein also comprises the medicine acceptable carrier.
7. the application of the Chinese medicine preparation of claim 1 in the medicine of preparation treatment gynaecological inflammation disease.
8, the preparation method of the Chinese medicine preparation of claim 1 is characterized in that, through following steps, Radix Picriae felterrae adds 3～12 times of water gagings and decocts each 0.5～3 hour 1～3 time, collecting decoction, centrifugal, styrene tyle macroporous adsorption resin on the filtrate, the water eluting discards water lotion, uses 20～95% ethanol and water elution more successively, merge eluent, reclaim ethanol, being concentrated into relative density is 1.05～1.35 (60 ℃), drying is ground into fine powder, and is standby; Herba Senecionis Scandentis, Radix Sophorae Flavescentis add 3～12 times of water gagings and decoct secondary, each 0.5～3 hour, collecting decoction, filter, it is 1.02～1.40 (60 ℃) that filtrate is concentrated into relative density, adds 85% ethanol and makes and contain the alcohol amount and reach 60%, fully stir, left standstill 4～24 hours, get supernatant, filter, filtrate recycling ethanol, being concentrated into relative density is 1.02～1.40 (60 ℃), drying, be ground into fine powder, standby; Cortex Phellodendri adds 3～12 times of amount 0.1～2.0% sulfuric acid solutions, decocts secondary, each 0.5～3 hour, collecting decoction filtered, filtrate is concentrated into 1.01～1.20 (60 ℃), adds the sodium chloride that is equivalent to extractum amount 15%, stirs, leave standstill, centrifugal, precipitate washes with water to pH value 2～7, and is centrifugal, drying precipitate, be ground into fine powder, standby; The watermelon crystal drying, be ground into fine powder, with above-mentioned fine powder mixing; Fructus Litseae adds 3～12 times of water gaging distillations 3～12 hours, collects volatile oil, and is standby; Borneolum Syntheticum powder is broken into fine powder, adds in the above-mentioned volatile oil, and slight fever makes dissolving, adds in the above-mentioned fine powder again, stirs evenly.
9, preparation method according to Claim 8 is characterized in that, through following steps, extract that the step of claim 8 obtains and fine powder are pharmaceutically active substance, presses pharmaceutical dosage form and adds adjuvant, makes preparation.
10, a kind of detection method is characterized in that, is a kind of detection method of the pharmaceutical preparation to claim 5, may further comprise the steps,
Character: this product is that yellowish-brown is to brown duckbill suppository; Special fragrance is arranged;
Differentiate: (1) gets 1 of this product, puts in the tool plug conical flask, and slight fever makes fusing, the 20ml that adds diethyl ether, and close plug jolting 2 minutes filters, and medicinal residues are standby, and filtrate is as need testing solution.Other gets the Borneolum Syntheticum reference substance, adds dehydrated alcohol and makes the solution that every 1ml contains 2mg; Get the citral reference substance again, add dehydrated alcohol and make the solution that every 1ml contains 5 μ 1, in contrast product solution.Test according to thin layer chromatography (an appendix VI of Chinese Pharmacopoeia version in 2000 B), draw each 1 μ l of above-mentioned three kinds of solution, put respectively in same be on the silica gel g thin-layer plate of adhesive with the sodium carboxymethyl cellulose, with petroleum ether (30～60 ℃)-ethyl acetate-benzene (12: 1: 2) is developing solvent, launch, take out, dry, spray is with the phosphomolybdic acid test solution, and it is clear to be heated to the speckle colour developing at 105 ℃.In the test sample chromatograph, with the corresponding position of reference substance chromatograph on, show the speckle of same color;
(2) get discriminating (1) medicinal residues down, volatilize ether, add methanol 10ml, supersound process 20 minutes, filtration, filtrate is as need testing solution.Other gets Cortex Phellodendri control medicinal material 0.15g, adds methanol 5ml, shines medical material solution in pairs with legal system.Get the berberine hydrochloride reference substance again, add methanol and make the solution that every 1ml contains 0.5mg, in contrast product solution.Test according to thin layer chromatography (an appendix VI of Chinese Pharmacopoeia version in 2000 B), draw each 2～4 μ l of above-mentioned three kinds of solution, put respectively in same be on the silica gel g thin-layer plate of adhesive with the sodium carboxymethyl cellulose, with benzene-ethyl acetate-methanol-isopropyl alcohol-strong ammonia solution (12: 6: 3: 3: 1) is developing solvent, with developing solvent and strong ammonia solution pre-equilibration 15 minutes simultaneously, launch, take out, dry, put under the ultra-violet lamp (365nm) and inspect.In the test sample chromatograph, with control medicinal material chromatograph and the corresponding position of reference substance chromatograph on, show the fluorescence speckle of same color;
(3) get 1 of this product, put in the tool plug conical flask, slight fever makes fusing, the 20ml that adds diethyl ether, close plug jolting 2 minutes, filter, medicinal residues volatilize ether, add chloroform 30ml, strong ammonia solution 0.5ml, supersound process 30 minutes, filter, filtrate evaporate to dryness, residue add chloroform 2ml makes dissolving, as need testing solution.Other gets the matrine reference substance, adds methanol and makes the solution that every 1ml contains 0.5mg, in contrast product solution.Test according to thin layer chromatography (an appendix VI of Chinese Pharmacopoeia version in 2000 B), draw need testing solution 4～6 μ l, reference substance solution 4 μ l, put respectively in same be on the silica gel g thin-layer plate of adhesive with the sodium carboxymethyl cellulose, with benzene-acetone-ethyl acetate-strong ammonia solution (2: 3: 4: 0.2) be developing solvent, launch, take out, dry, spray is with bismuth potassium iodide test solution.In the test sample chromatograph, with the corresponding position of reference substance chromatograph on, show the speckle of same color;
Check: pH value is got 2 of this product, adds water 40ml, puts in the hot bath, makes fusing, stirs, and puts coldly, filters, and measures (an appendix VII of Chinese Pharmacopoeia version in 2000 G) in accordance with the law, should be 4.0～5.5;
Other: should meet every regulation relevant under the suppository item (appendix IW of Chinese Pharmacopoeia version in 2000); Assay: measure according to high performance liquid chromatography (an appendix VI of Chinese Pharmacopoeia version in 2000 D); Chromatographic condition and system suitability test are filler with octadecylsilane chemically bonded silica; Acetonitrile-water-glacial acetic acid (38: 62: 0.5) is a mobile phase; The detection wavelength is 264nm.Number of theoretical plate calculates by Radix Picriae felterrae glycosides IA peak should be not less than 5000;
The preparation of reference substance solution: it is an amount of that precision takes by weighing Radix Picriae felterrae glycosides IA reference substance, adds methanol and make the solution that every 1ml contains 0.1mg, in contrast product solution;
The preparation of need testing solution: get 10 of this product, the accurate title, decide, and grinds, and gets about 2g, the accurate title, decide, and puts in the tool plug conical flask, and the accurate methanol 20ml that adds claims to decide weight, supersound process 45 minutes is put coldly, claims to decide weight again, supplies the weight that subtracts mistake with methanol, shake up, filter, getting subsequent filtrate, to put refrigerator freezing, after treating that suppository base solidifies, take out, centrifugal, get supernatant, be placed to room temperature, promptly;
Algoscopy: accurate respectively reference substance solution and each 20 μ l of need testing solution of drawing, inject chromatograph of liquid, measure, calculate, promptly; Every of this product contains Radix Picriae felterrae with Radix Picriae felterrae glycosides I
A(C
41H
62O
13) meter, must not be less than 1.6mg.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB200410058110XA CN1315506C (en) | 2004-08-13 | 2004-08-13 | Chinese medicine preparation for treating gynecologic inflammation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB200410058110XA CN1315506C (en) | 2004-08-13 | 2004-08-13 | Chinese medicine preparation for treating gynecologic inflammation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1586517A true CN1586517A (en) | 2005-03-02 |
| CN1315506C CN1315506C (en) | 2007-05-16 |
Family
ID=34603320
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB200410058110XA Expired - Lifetime CN1315506C (en) | 2004-08-13 | 2004-08-13 | Chinese medicine preparation for treating gynecologic inflammation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1315506C (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102274341A (en) * | 2010-06-10 | 2011-12-14 | 上海中医药大学 | Extracting and refining process for medicinal components of figwort root |
| CN103623185A (en) * | 2013-12-05 | 2014-03-12 | 丛建香 | External application traditional Chinese medicine for treating gynecologic inflammation |
-
2004
- 2004-08-13 CN CNB200410058110XA patent/CN1315506C/en not_active Expired - Lifetime
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102274341A (en) * | 2010-06-10 | 2011-12-14 | 上海中医药大学 | Extracting and refining process for medicinal components of figwort root |
| CN103623185A (en) * | 2013-12-05 | 2014-03-12 | 丛建香 | External application traditional Chinese medicine for treating gynecologic inflammation |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1315506C (en) | 2007-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100342889C (en) | Chinese medicine for treating gout | |
| CN101708241B (en) | Medicinal composition for eliminating dampness and relieving itching | |
| CN100353968C (en) | Chinese medicine preparation for nourishing blood and tranquilizing mind and its preparation process | |
| CN103690582B (en) | A kind of compositions and application thereof containing dendrobium polysaccharide and atractylis concrete | |
| CN1709454A (en) | Chinese medicine formulation for treating arthrolithiasis, and its preparing method | |
| CN102671178A (en) | Chinese medicinal composition for treating nephrotic syndrome and uremia and preparation method and application thereof | |
| CN1679706A (en) | Medicinal preparation containing notoginseng and rhodiola root for cardio-cerebral blood vessel diseases and its preparing method | |
| CN113952419B (en) | Pharmaceutical composition for chronic renal failure and preparation method and application thereof | |
| CN1943734B (en) | A Chinese traditional medicine for clearing away heat and toxic material | |
| CN102370901A (en) | Pharmaceutical composition for treating nephrosis and preparing process thereof | |
| CN1679698A (en) | Medicinal preparation containing notoginseng and lovge rhizome for treating cardio-cerebral blood vessel diseases and its preparing method | |
| CN1315506C (en) | Chinese medicine preparation for treating gynecologic inflammation | |
| CN102048841A (en) | Lactogenic traditional Chinese medicine composition and preparation method thereof | |
| CN1977900A (en) | Chinese medicine for treating skin disease such as psoriasis | |
| CN1679701A (en) | Medicinal preparation containing notoginseng and saflower for treating cardio-cerebral blood diseases and its preparing method | |
| CN1259950C (en) | Chinese medical preparation and its preparing process | |
| CN1220513C (en) | Proprietury Chinese medicine for stopping blood, analgesia, removing blood stasis and engender new and its preparation method | |
| CN101077364A (en) | Traditional Chinese medicine composition for treating cardio cerebrovasculer disease and its preparations and preparation method | |
| CN1416880A (en) | New use of powder for regulating liver and spleen and its active part | |
| CN104857043A (en) | Radix bupleuri extract and preparation method thereof | |
| CN1289110C (en) | Capsule preparation for treating gynecological diseases and preparation process thereof | |
| CN102370903B (en) | Pharmaceutical composition for treating nephrosis and preparation method thereof | |
| CN107137633B (en) | Kidney-tonifying and turbidity-removing traditional Chinese medicine composition and application thereof | |
| CN105327219A (en) | Traditional Chinese medicine composition for treating female pelvic inflammation and preparation method of traditional Chinese medicine composition | |
| CN1068228C (en) | Medicine for reducing pathologic raised beta-receptor and its producing tehcnology |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: SANJIN PHARMACEUTICAL CO., LTD., GUILIN Free format text: FORMER OWNER: GUILIN SANJIN BIOLOGICAL PHARMACEUTICAL CO., LTD., SANJIN GROUP Effective date: 20130424 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 541100 GUILIN, GUANGXI ZHUANG AUTONOMOUS REGION TO: 541004 GUILIN, GUANGXI ZHUANG AUTONOMOUS REGION |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20130424 Address after: 541004 No. 1 Jinxing Road, Guilin, the Guangxi Zhuang Autonomous Region Patentee after: GUILIN SANJIN PHARMACEUTICAL Co.,Ltd. Address before: 541100 No. 112 Renmin Avenue, the Guangxi Zhuang Autonomous Region, Guilin, Xicheng District Patentee before: GUILIN SANJIN BIOLOG PHARMACEU |
|
| CX01 | Expiry of patent term | ||
| CX01 | Expiry of patent term |
Granted publication date: 20070516 |